CV Technologies changes name
This article was originally published in The Tan Sheet
Executive SummaryThe Cold-FX manufacturer changes its name to Afexa Life Sciences as part of a broader rebranding plan. CV Technologies "did not convey our rigorous life sciences orientation, or support our plans to leverage our market-leading product as we launch new ones," Executive Chairman Jack Moffatt says April 1 after shareholders approved the name change. The Canadian company said in November that it may submit a new drug application to FDA and look to grow its presence the U.S. market (1"The Tan Sheet" Nov. 24, 2008, p. 9)
You may also be interested in...
In an exclusive interview with Medtech Insight, Mark Leahey, president of the Medical Device Manufacturers Association (MDMA), said the previous four Medical Device User Fee negotiations with the US FDA have set a strong foundation for the industry and the next round of negotiations should focus on tweaking past deals that are already in place. See what MDMA's president, Mark Leahey, said about it here.
US investigators fan out to non-China inspection priorities and Secretary Azar talks supply management; warning letters hit record keeping, investigations and basic GMP compliance.